Across the Americas, Europe and Asia, the Aquavit Group of Companies advances one body of protected science — in pharmaceutical development, manufacturing and research, applied intelligence, skin health, and the stewardship of long-held interests. Each company holds focus in its own discipline; the group expands into each market where that science can reach patients.
Science personalized. Healthcare modernized.
The heritage company, and the origin of the science that the other companies apply.
Develops and protects drugs, biologics and devices built around personalized treatment systems and precision delivery. Programs run across neuroscience, oncology, medical dermatology, medical aesthetics and immunology, from commercial-stage systems to early research.
Operating since 2010. It holds the founding patent family, whose earliest priority date is January 2011.
Company →The Swiss enterprise, uniting drug, biologic and device development with intellectual property, proprietary artificial intelligence and financial strategy.
In 2025 it acquired Axon Technologies AG — formerly Genève Technologies — bringing predictive modeling, drug-discovery pipelines, AI-powered PITO (Personalized Injection Treatment Optimizer), clinical-trial data analysis and an AI-powered global commercial healthcare platform in-house.
Its proprietary engines include Compliance AI™, addressing regulatory clearance and reimbursement across jurisdictions, and Territory X™ AI, orchestrating distribution and demand across territories.
Company →Where the devices are made, and where quality is controlled directly rather than at arm's length.
Provides cGMP manufacturing and research capability under ISO-certified quality systems, supplying the delivery and preparation technologies developed elsewhere in the portfolio.
Holding manufacturing close rather than contracting it out does more than raise capacity: it lets drugs, biologics and devices be developed in parallel rather than in sequence.
Company →Dermatology and aesthetics — the discipline in which the delivery science first met patients.
Spans the medical and the aesthetic: microchannel delivery of physician-selected agents, personalized preparation, dermal augmentation, and clinical programs in atopic dermatitis, plaque psoriasis, hyperhidrosis, alopecia and micro-skin-anesthesia.
Alongside the clinical work sits a consumer line and a skin assessment platform.
Company →The companies that hold and steward interests associated with the Aquavit name.
Those interests include licensing and asset rights in therapeutic programs, held separately from the companies that develop and commercialize them — long-horizon assets whose value compounds through careful custody rather than day-to-day operation.
Company →The first and only research organization dedicated to botulinum toxin research.
A 501(c)(3) non-profit, supporting independent research from bench to bedside — the fundamental science through to clinical practice. Aquavit is a proud sponsor of its work.
For partnership, scientific collaboration and media inquiries, write to us.
